| Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications (NCT00799461) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2008-08-01 |
| Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia (NCT00703300) | National Cancer Institute (NCI) | 2008-06-01 |
| Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT00475150) | National Cancer Institute (NCI) | 2008-05-01 |
| Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia (NCT00666588) | National Cancer Institute (NCI) | 2008-04-01 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders (NCT00588991) | National Cancer Institute (NCI) | 2008-02-04 |
| Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00602225) | University of Washington | 2007-12-01 |
| Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01093586) | Case Comprehensive Cancer Center | 2007-09-01 |
| Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer (NCT00540995) | City of Hope Medical Center | 2007-06-11 |
| MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia (NCT00462605) | National Cancer Institute (NCI) | 2007-04-01 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (NCT00489203) | Fred Hutchinson Cancer Center | 2007-04-01 |
| Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia (NCT00470197) | National Cancer Institute (NCI) | 2007-04-01 |
| GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia (NCT00459212) | National Cancer Institute (NCI) | 2007-03-01 |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (NCT00445744) | Fred Hutchinson Cancer Center | 2006-12-01 |
| Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00392353) | National Cancer Institute (NCI) | 2006-11-22 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis (NCT00387426) | National Cancer Institute (NCI) | 2006-09-01 |
| Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00313586) | National Cancer Institute (NCI) | 2006-08-01 |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase (NCT00383474) | National Cancer Institute (NCI) | 2006-08-01 |
| High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (NCT00536601) | Roswell Park Cancer Institute | 2006-06-29 |
| Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases (NCT00357708) | National Cancer Institute (NCI) | 2006-06-01 |
| Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (NCT00408681) | Fred Hutchinson Cancer Center | 2006-06-01 |
| Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (NCT00351975) | National Cancer Institute (NCI) | 2006-06-01 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00357305) | National Cancer Institute (NCI) | 2006-05-01 |
| PXD101 in Treating Patients With Acute Myeloid Leukemia (NCT00357032) | National Cancer Institute (NCI) | 2006-05-01 |
| Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes (NCT00331513) | National Cancer Institute (NCI) | 2006-03-01 |
| Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia (NCT00275080) | National Cancer Institute (NCI) | 2006-02-01 |
| Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia (NCT00322101) | Fred Hutchinson Cancer Center | 2006-01-01 |
| Vorinostat in Treating Patients With Acute Myeloid Leukemia (NCT00305773) | National Cancer Institute (NCI) | 2006-01-01 |
| Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia (NCT00278330) | National Cancer Institute (NCI) | 2006-01-01 |
| 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes (NCT00301938) | National Cancer Institute (NCI) | 2005-12-01 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia (NCT00301769) | National Cancer Institute (NCI) | 2005-12-01 |
| Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00131989) | National Cancer Institute (NCI) | 2005-06-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT00103272) | National Cancer Institute (NCI) | 2005-04-01 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00118352) | Fred Hutchinson Cancer Center | 2005-03-01 |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes (NCT00098826) | National Cancer Institute (NCI) | 2004-12-01 |
| MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00101179) | National Cancer Institute (NCI) | 2004-11-03 |
| Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00105001) | Fred Hutchinson Cancer Center | 2004-11-01 |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes (NCT00098423) | National Cancer Institute (NCI) | 2004-11-01 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00101296) | National Cancer Institute (NCI) | 2004-10-01 |
| XK469R in Treating Patients With Refractory Hematologic Cancer (NCT00095797) | National Cancer Institute (NCI) | 2004-10-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00101231) | National Cancer Institute (NCI) | 2004-10-01 |
| Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies (NCT01056614) | Fred Hutchinson Cancer Center | 2004-09-01 |
| S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia (NCT00093418) | National Cancer Institute (NCI) | 2004-09-01 |
| Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission (NCT00093470) | National Cancer Institute (NCI) | 2004-08-18 |
| Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia (NCT00087204) | National Cancer Institute (NCI) | 2004-05-01 |
| CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase (NCT00084916) | National Cancer Institute (NCI) | 2004-04-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00079378) | National Cancer Institute (NCI) | 2004-02-01 |
| 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies (NCT00077181) | National Cancer Institute (NCI) | 2004-01-01 |
| GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia (NCT00070551) | National Cancer Institute (NCI) | 2003-09-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT00119366) | Fred Hutchinson Cancer Center | 2003-05-01 |
| Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00062075) | National Cancer Institute (NCI) | 2003-05-01 |
| Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant (NCT00068718) | Fred Hutchinson Cancer Center | 2003-05-01 |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (NCT00060372) | National Cancer Institute (NCI) | 2003-04-01 |
| Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00049582) | National Cancer Institute (NCI) | 2002-09-01 |
| Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant (NCT00052598) | Fred Hutchinson Cancer Center | 2002-09-01 |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation (NCT00052520) | Fred Hutchinson Cancer Center | 2002-09-01 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (NCT00039091) | National Cancer Institute (NCI) | 2002-03-01 |
| Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00027820) | Fred Hutchinson Cancer Center | 2001-08-01 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (NCT00025415) | National Cancer Institute (NCI) | 2001-08-01 |
| Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia (NCT00017472) | National Cancer Institute (NCI) | 2001-04-01 |
| Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia (NCT00016016) | National Cancer Institute (NCI) | 2001-02-01 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |
| BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia (NCT00006213) | National Cancer Institute (NCI) | 2000-04-01 |
| PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome (NCT00005064) | National Cancer Institute (NCI) | 2000-02-01 |
| Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00005799) | Fred Hutchinson Cancer Center | 1999-11-01 |
| Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes (NCT00008177) | Fred Hutchinson Cancer Center | 1999-07-27 |
| Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia (NCT00003875) | Fred Hutchinson Cancer Center | 1998-10-13 |
| High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma (NCT01177371) | Case Comprehensive Cancer Center | 1988-03-01 |
| Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (NCT01869803) | Wake Forest University Health Sciences | |